Processa Pharmaceuticals

Processa Pharmaceuticals Liabilities

The The Liabilities of Processa Pharmaceuticals (PCSA) as of Oct 28, 2026 is 2.24 M USD. In the previous year, The Liabilities was 1.53 M USD — a change of 45.86% (higher).

Liabilities

2.24 MUSD

YoY

45.86%

Last updated:

In 2025, Processa Pharmaceuticals's total liabilities amounted to 2.24 M USD, a 45.86% difference from the 1.53 M USD total liabilities in the previous year.

The Processa Pharmaceuticals Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
3.51 M USD
Jan 1, 2019
2.87 M USD
Jan 1, 2020
2.27 M USD
Jan 1, 2021
978,405.00 USD
Jan 1, 2022
1.15 M USD
Jan 1, 2023
797,484.00 USD
Jan 1, 2024
1.53 M USD
Jan 1, 2025
2.24 M USD
The Processa Pharmaceuticals Liabilities history
YEARLiabilitiesYoY
2.24 MUSD+45.86%
1.53 MUSD+92.24%
797,484.00USD-30.60%
1.15 MUSD+17.45%
978,405.00USD-56.99%
2.27 MUSD-20.75%
2.87 MUSD-18.30%
3.51 MUSD+34.63%
2.61 MUSD+25.28%
2.08 MUSD0.00%
2.08 MUSD+56.14%
1.33 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Processa Pharmaceuticals Stock analysis

What does Processa Pharmaceuticals do? Processa Pharmaceuticals Inc develops drug products targeting serious medical conditions with unmet patient needs. The company focuses on improving survival and quality of life through its portfolio of 499 products, including 499 for Necrobiosis Lipoidica and 499 for head and neck cancer treatment. It generates revenue through the development and commercialization of these pharmaceutical solutions, primarily selling to healthcare providers and institutions that treat patients with these specific conditions. The firm's primary market segment consists of medical professionals and facilities specializing in dermatology and oncology. Processa Pharmaceuticals Inc's business model centers on drug development for niche therapeutic areas where patient demand remains underserved. The company's product pipeline includes 499 for two distinct medical applications, allowing it to target specialized healthcare markets. Revenue streams are derived from the commercialization phase of these drug development projects once regulatory approval is secured. The company's focus on specific medical conditions enables it to build targeted relationships with healthcare providers in dermatology and oncology sectors. The firm's revenue generation relies on the successful development and subsequent sale of its pharmaceutical products. By concentrating on Necrobiosis Lipoidica and head and neck cancer treatments, Processa Pharmaceuticals Inc serves specialized medical communities requiring advanced therapeutic options. Its business model does not include traditional pharmaceutical sales channels but rather focuses on developing and licensing drug products for these specific medical applications. Processa Pharmaceuticals is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Processa Pharmaceuticals's Liabilities

Processa Pharmaceuticals's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Processa Pharmaceuticals's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Processa Pharmaceuticals's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Processa Pharmaceuticals's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Processa Pharmaceuticals’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Processa Pharmaceuticals stock

The Liabilities of Processa Pharmaceuticals is 2.24 M USD in 2025.

The Liabilities of Processa Pharmaceuticals changed from 1.53 M USD to 2.24 M USD, representing a 45.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Processa Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Processa Pharmaceuticals historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Processa Pharmaceuticals

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Processa Pharmaceuticals